ResMed: Interim result 2015

New products have driven an excellent first-half performance for this quality healthcare company.

After a first-quarter full of promise, ResMed delivered the goods in its second quarter, with revenues of US$423m and earnings per ASX-listed share of US6.4c, ahead of forecasts for US$410m and US6.3c respectively.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles